A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial
- DOI
- 10.1016/j.vaccine.2026.128304
- Published
- 2026-03
- Container
- Vaccine
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.vaccine.2026.128304,
title = {A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial},
author = {Temitope Oyedele and Rachel Park and Kelly Morales and Manish Jain and Lawrence Sher and Apinya Vutikullird and Abby Isaacs and Brett Jepson and Kathryn Shoemaker and Ann Marie Stanley and Joseph Lee and Cindy Handelsman and Stacey Cromer Berman and Lee-Jah Chang},
year = {2026},
journal = {Vaccine},
doi = {10.1016/j.vaccine.2026.128304},
url = {https://doi.org/10.1016/j.vaccine.2026.128304}
}RIS
TY - JOUR TI - A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial AU - Temitope Oyedele AU - Rachel Park AU - Kelly Morales AU - Manish Jain AU - Lawrence Sher AU - Apinya Vutikullird AU - Abby Isaacs AU - Brett Jepson AU - Kathryn Shoemaker AU - Ann Marie Stanley AU - Joseph Lee AU - Cindy Handelsman AU - Stacey Cromer Berman AU - Lee-Jah Chang PY - 2026 JO - Vaccine DO - 10.1016/j.vaccine.2026.128304 UR - https://doi.org/10.1016/j.vaccine.2026.128304 ER -
APA
Oyedele, T., Park, R., Morales, K., Jain, M., Sher, L., Vutikullird, A., Isaacs, A., Jepson, B., Shoemaker, K., Stanley, A. M., Lee, J., Handelsman, C., Berman, S. C., & Chang, L. (2026). A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial. Vaccine. https://doi.org/10.1016/j.vaccine.2026.128304
Source records
- crossref · retrieved 2026-09-26T14:14:39.577Z